II 

117TH CONGRESS 

2D SESSION S. 3617 

To amend the Office of National Drug Control Policy Reauthorization Act 

of 2006 to modify the authority of the Office of National Drug Control 

Policy and the United States Anti-Doping Agency, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

FEBRUARY 9, 2022 

Mrs. BLACKBURN introduced the following bill; which was read twice and 

referred to the Committee on Commerce, Science, and Transportation 

A BILL 

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the 

Office of National Drug Control Policy and the United 

States Anti-Doping Agency, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Restoring Confidence 

5 to the World Anti-Doping Agency Act of 2022’’. 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•S 3617 IS

1 SEC. 2. AUTHORITY OF THE UNITED STATES ANTI-DOPING 

2 AGENCY WITH RESPECT TO THE WORLD 

3 ANTI-DOPING AGENCY. 

4 Section 701 of the Office of National Drug Control 

5 Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is 

6 amended— 

7 (1) in subsection (a)— 

8 (A) by amending paragraph (1) to read as 

9 follows: 

10 ‘‘(1) UNITED STATES OLYMPIC AND

11 PARALYMPIC COMMITTEE.—The term ‘United States 

12 Olympic and Paralympic Committee’ means the or13 ganization established by chapter 2205 of title 36, 

14 United States Code.’’; 

15 (B) by redesignating paragraphs (1) and 

16 (3) as paragraphs (4) and (1), respectively, and 

17 moving the paragraphs so as to appear in nu18 meric order; and 

19 (C) by inserting after paragraph (2) the 

20 following: 

21 ‘‘(3) INDEPENDENT ATHLETE.—The term 

22 ‘independent athlete’ means an amateur athlete who 

23 does not serve, in any capacity, in— 

24 ‘‘(A) the International Olympic Committee; 

25 ‘‘(B) the International Paralympic Com26 mittee; 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•S 3617 IS

1 ‘‘(C) an international sports federation rec2 ognized by the International Olympic Com3 mittee or the International Paralympic Com4 mittee; 

5 ‘‘(D) the United States Olympic and 

6 Paralympic Committee; or 

7 ‘‘(E) the World Anti-Doping Agency.’’; 

8 (2) in subsection (b)— 

9 (A) by striking ‘‘United States Olympic 

10 Committee’’ each place it appears and inserting 

11 ‘‘United States Olympic and Paralympic Com12 mittee’’; 

13 (B) in paragraph (4), by striking the pe14 riod at the end and inserting ‘‘; and’’; and 

15 (C) by adding at the end the following: 

16 ‘‘(5) carry out responsibilities with respect to 

17 the World Anti-Doping Agency, as described in sub18 section (c).’’; and 

19 (3) by adding at the end the following: 

20 ‘‘(c) AUTHORITY WITH RESPECT TO THE WORLD

21 ANTI-DOPING AGENCY.— 

22 ‘‘(1) IN GENERAL.—The Office of National 

23 Drug Control Policy, in conjunction with the United 

24 States Anti-Doping Agency, shall— 


pamtmann on DSKBC07HB2PROD with BILLS
4 

•S 3617 IS

1 ‘‘(A) use all available tools to ensure 

2 that— 

3 ‘‘(i) the World Anti-Doping Agency 

4 maintains a proper conflict-of-interest pol5 icy that prohibits an individual from serv6 ing as a member of the Executive Com7 mittee of the World Anti-Doping Agency if, 

8 during the preceding 2-year period, the in9 dividual served in any capacity for a sports 

10 federation that is or was under the juris11 diction of the World Anti-Doping Agency; 

12 and 

13 ‘‘(ii) independent athletes from the 

14 United States and other democratic coun15 tries, or representatives of such athletes, 

16 have voting positions on the Executive 

17 Committee and governing bodies of the 

18 World Anti-Doping Agency, including the 

19 foundation board and all standing commit20 tees and working groups; 

21 ‘‘(B) demonstrate leadership within the 

22 global community; 

23 ‘‘(C) have strict standards that work to24 ward countering the state-sponsored doping sysVerDate Sep 11 2014 16:50 Feb 15, 2022 Jkt 029200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S3617.IS S3617

pamtmann on DSKBC07HB2PROD with BILLS
5 

•S 3617 IS

1 tem of the Russian Federation and other state2 sponsored, systemic fraud through doping; and 

3 ‘‘(D) work collaboratively with democratic 

4 countries. 

5 ‘‘(2) DETERMINATION.— 

6 ‘‘(A) IN GENERAL.—Not later than 90 

7 days after the date of the enactment of this 

8 subsection, the Office of National Drug Control 

9 Policy, in conjunction with the United States 

10 Anti-Doping Agency, shall make a determina11 tion as to whether the World Anti-Doping 

12 Agency— 

13 ‘‘(i) has a credible and independent 

14 governance model that provides for fair 

15 representation of the United States; 

16 ‘‘(ii) maintains a conflict-of-interest 

17 policy described in paragraph (1)(A)(i); 

18 and 

19 ‘‘(iii) allows independent athletes from 

20 the United States and other democratic 

21 countries, or representatives of such ath22 letes, to have voting positions on the Exec23 utive Committee and governing bodies of 

24 the World Anti-Doping Agency, including 


pamtmann on DSKBC07HB2PROD with BILLS
6 

•S 3617 IS

1 the foundation board and all standing com2 mittees and working groups. 

3 ‘‘(B) ACCOUNTABILITY.—In the case of a 

4 determination under subparagraph (A) that the 

5 World Anti-Doping Agency does not have such 

6 a governance model, maintain such a conflict7 of-interest policy, or allow such voting positions, 

8 the Office of National Drug Control Policy, in 

9 conjunction with the United States Anti-Doping 

10 Agency, shall— 

11 ‘‘(i) submit a request to the Govern12 ment Accountability Office to indicate the 

13 amount of United States taxpayer dollars 

14 used to pay dues to the World Anti-Doping 

15 Agency; 

16 ‘‘(ii) demand that the United States 

17 have fair representation in World Anti18 Doping Agency, including not fewer than 

19 one representative on each of— 

20 ‘‘(I) the Executive Committee of 

21 the World Anti-Doping Agency; and 

22 ‘‘(II) any other governing body of 

23 the World Anti-Doping Agency for 

24 which the United States pays dues; 

25 and 


pamtmann on DSKBC07HB2PROD with BILLS
7 

•S 3617 IS

1 ‘‘(iii) issue a report that describes the 

2 justifications, and the countries respon3 sible, for blocking the United States from 

4 the Executive Committee of the World 

5 Anti-Doping Agency. 

6 ‘‘(3) UNITED STATES PARTICIPATION IN EXEC7 UTIVE COMMITTEE OF THE WORLD ANTI-DOPING

8 AGENCY.— 

9 ‘‘(A) IN GENERAL.—As a condition of 

10 United States participation in the World Anti11 Doping Agency— 

12 ‘‘(i) the United States shall be allotted 

13 not fewer than one seat on the Executive 

14 Committee of the World Anti-Doping 

15 Agency for as long as such Executive Com16 mittee is a representative body as struc17 tured on the date of the enactment of this 

18 subsection; and 

19 ‘‘(ii) the World Anti-Doping Agency 

20 shall make a legal commitment to the Of21 fice of National Drug Control Policy and 

22 the United States Anti-Doping Agency 

23 that states there will be not fewer than one 

24 representative of the United States on such 

25 Executive Committee at all times. 


pamtmann on DSKBC07HB2PROD with BILLS
8 

•S 3617 IS

1 ‘‘(B) REFUND OF DUES.—If such Execu2 tive Committee appoints not fewer than one 

3 representative of the United States during the 

4 one-year period beginning on the date of the en5 actment of this subsection, the Office of Na6 tional Drug Control Policy or the United States 

7 Anti-Doping Agency may not appeal to the 

8 World Anti-Doping Agency for a refund of dues 

9 paid during the period in which the United 

10 States did not have a representative on such 

11 Executive Committee.’’. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS